CSIMarket
 
China Pediatric Pharmaceuticals, Inc.  (CPDU)
Other Ticker:  
 
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

China Pediatric Pharmaceuticals, Inc.
China Pediatric Pharmaceuticals, Inc. is a company that operates in the pharmaceutical industry, specifically focused on pediatric medications. The company is based in China and specializes in developing, producing, and distributing pharmaceutical products for children. They aim to provide safe, effective, and high-quality medications to meet the unique healthcare needs of pediatric patients. China Pediatric Pharmaceuticals, Inc. may engage in research and development activities to create innovative pediatric drugs and may also collaborate with healthcare professionals and institutions to improve pediatric healthcare and treatment outcomes.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Sonida Senior Living Inc

In spite of Strong revenue Profitability not Reached by at the Sonida Senior Living Inc in the October to December 31 2023 span

Although Sonida Senior Living Inc s' revenue increased by 10.407 % from the same reporting season a year before to $65.72 million in the October to December 31 2023 span, the Healthcare Facilities company Deficit has widen at $-1.76 deficit per share. To placeSonida Senior Living Inc s'fourth quarter of 2023 behavior, we must analyze the on averageHealthcare Facilities industries, it is becoming obvious, that Sonida Senior Living Inc has come in short of as the contemporaries release top-line advance of 14.04% from the same reporting season a year ago.

The Oncology Institute Inc

The Oncology Institute Inc declared very challenging period, over the fourth quarter of 2023

the Healthcare Facilities company declared disastrous most recent fiscal period, where Revenue faded by -66.022 % to $85.79 million and a shortfall per share has swelled to $-0.05, from the comparable reporting period a year prior. Conflicting to the the TOIs' development the remainder ofHealthcare Facilities industry, posted a revenue 14.04% rise compared to the comparable period a year before in the fourth quarter of 2023.

Cardiff Lexington Corporation

Cardiff Lexington Corporation Demonstrates Resilience Despite Tough Financial Period

Cardiff Lexington Corporation, despite facing a tough financial interval closing on December 31, 2023, has managed to achieve significant improvements and display resilience in the face of adversity. While CDIF's gain per share remained at $0.00, it is important to note that this is a significant leap from the previous year's loss of $-0.01 per share.
Furthermore, CDIF's revenue experienced a considerable decline of -19.263% to $2.07 million from $2.57 million in the same reporting period a year ago. However, it is important to highlight that this dip was also seen across the entire Healthcare Facilities sector, making CDIF's performance in line with industry trends. Additionally, there was a sequential decrease of -39.748% from $3.44 million, indicating some challenges faced during the reporting period.

Lifemd Inc

Healthcare Facilities company sees surge in revenue and reduction in deficit during recent fiscal period

Lifemd Inc, a renowned provider of virtual primary care services, has shown impressive growth in its most recent fiscal period. The company reported an energetic revenue rise of 64.276% to $45.50 million, which helped reduce losses to $-0.11 per share compared to $-0.36 per share in the corresponding reporting period a year ago. This significant improvement is a positive sign for investors and indicates that Lifemd Inc is on track to achieve profitability.
In contrast to the previous quarter, where revenue improved by 20.279% from $37.83 million, Lifemd Inc's income per share also witnessed improvement, increasing from $-0.20 per share. These positive developments highlight the company's strong performance and efficient cost management strategies.

Enhabit Inc

Enhabit Inc Reports $-0.13 per Share Deficit in Fiscal Fourth Quarter of 2023

Enhabit Inc, a home health and hospice care provider, has recently reported its financial results for the fiscal period ending in December 2023. The company recorded a loss of $-0.13 per share, compared to a loss of $-0.05 per share in the preceding reporting period. This represents a decrease in earnings from the same reporting period a year ago, where the company reported a loss of $-1.39 per share.
Despite the decrease in earnings per share, Enhabit Inc saw a slight increase in revenue of 0.89% from the previous reporting period, totaling $258.30 million. The company also reported a significant decrease in net deficit from $-68.000 million in the same reporting period a year ago to $-5.900 million in the current period.






 

China Pediatric Pharmaceuticals's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com